--- title: "JOINT | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.82 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285608198.md" datetime: "2026-05-07T20:07:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285608198.md) - [en](https://longbridge.com/en/news/285608198.md) - [zh-HK](https://longbridge.com/zh-HK/news/285608198.md) --- # JOINT | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.82 M Revenue: As of FY2026 Q1, the actual value is USD 14.82 M, beating the estimate of USD 14.5 M. EPS: As of FY2026 Q1, the actual value is USD 0.09. EBIT: As of FY2026 Q1, the actual value is USD 631.92 K. #### Q1 2026 Financial Highlights (Year-over-Year Improvements) - **Revenue From Continuing Operations**: Increased by 13%. - **Adjusted EBITDA From Continuing Operations**: Improved by +$2.2 million. - **Net Income From Continuing Operations**: Increased by +$1.6 million. - **Free Cash Flow**: Improved by +$2.3 million. - **Cash Flow from Operating Activities**: Improved by $2.2 million. #### Q1 2026 Operating Metrics - **System-wide Sales**: Totaled $126.1 million, a decrease of -4.9% compared to Q1 2025. - **Comp Sales**: Decreased by -4.2% compared to Q1 2025. - **Consolidated Adjusted EBITDA**: Reached $3.5 million, an increase of 22% compared to Q1 2025. - **Total Clinics Open**: 943 at quarter-end Q1 2026. #### Detailed Financials (Three Months Ended March 31, 2026 vs. 2025) - **Revenue**: $14.8 million in Q1 2026, up from $13.1 million in Q1 2025, a difference of +$1.7 million. - **Cost of Revenues**: $2.7 million in Q1 2026, down from $3.0 million in Q1 2025, a difference of -$0.3 million. - **Selling and Marketing**: $3.7 million in Q1 2026, up from $3.5 million in Q1 2025, a difference of +$0.2 million. - **G&A Expenses**: $7.1 million in Q1 2026, up from $6.9 million in Q1 2025, a difference of +$0.2 million. - **Net Income from Continuing Operations**: $1.1 million in Q1 2026, up from -$0.5 million in Q1 2025, a difference of +$1.6 million. - **Consolidated Net Income**: $1.3 million in Q1 2026, up from $1.0 million in Q1 2025, a difference of +$0.3 million. - **Consolidated Adjusted EBITDA**: $3.5 million in Q1 2026, up from $2.9 million in Q1 2025, a difference of +$0.6 million. - **Cash Flows Used in Operating Activities**: -$1,476,170 in Q1 2026, an improvement from -$3,700,654 in Q1 2025. - **Free Cash Flow**: -$1,710,770 in Q1 2026, an improvement from -$4,032,159 in Q1 2025. #### Capital Allocation and Refranchising - The Joint Corp. signed an Asset Purchase Agreement in April 2026 for the sale of 45 corporate-owned or managed clinics for $2.3 million. - A Letter of Intent for the sale of five additional corporate-owned or managed clinics was made in Q1 2026, which will leave only three company-owned clinics remaining after these agreements. - The company repurchased 137,000 shares for $1.1 million during Q1 2026, at an average price of $8.35 per share, with $4.5 million remaining on the share repurchase plan. - Recent buybacks of three Regional Developer (RD) territories are expected to reduce RD royalties by approximately $450,000 on an annualized basis. - Unrestricted cash stood at $20.7 million as of March 31, 2026. #### Credit Agreement Amendment and Covenants - On May 1, 2026, The Joint Corp. entered into a waiver and fourth amendment to its existing credit agreement, addressing an existing default due to a violation of its fixed charge coverage ratio covenant for the fiscal quarter ending December 31, 2025. - The revolving credit maturity date has been extended to August 31, 2029. - The fixed charge coverage ratio definition was amended, reducing the amount of Restricted Payments subtracted in the ratio calculation by up to $10,000,000 for Q1-Q3 2026 and up to $5,000,000 for Q4 2026. - A new covenant requires The Joint Corp. to maintain a minimum liquidity of not less than $10,000,000 at any time during the period from January 1, 2026, to December 31, 2026. #### Outlook / Guidance The Joint Corp. reiterated its 2026 guidance, expecting system-wide sales between $519 million and $552 million, and consolidated Adjusted EBITDA between $12.5 million and $13.5 million. The company anticipates comp sales to range from -3% to 3% and projects 30 to 35 new franchised clinic openings. Management expects comp sales trends to improve throughout the balance of 2026. ### Related Stocks - [JYNT.US](https://longbridge.com/en/quote/JYNT.US.md) ## Related News & Research - [Charles Jobson Buys 5,240 Shares of Joint (NASDAQ:JYNT) Stock](https://longbridge.com/en/news/272002974.md) - [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md) - [Hilton Grand Vacations Wins 14 ARDA Awards | HGV Stock News](https://longbridge.com/en/news/286429274.md) - [Select Medical, Carilion Clinic form joint venture for Roanoke rehab hospital](https://longbridge.com/en/news/287225626.md) - [Why AST SpaceMobile Is the Bigger Winner of the AT&T, T-Mobile, and Verizon Joint Venture](https://longbridge.com/en/news/287077022.md)